This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.
Frontiers in endocrinology, 16, 1716247
Citation
Kolodziej, Maciej; Opalinska, Marta; Mikolajczak, Renata; Hubalewska-Dydejczyk, Alicja; Dedecjus, Marek; Kowalska, Aldona; Saracyn, Marek; Garnuszek, Piotr; Cieszykowska, Izabela; Januszkiewicz-Caulier, Joanna; Dlugosinska, Joanna; Durma, Adam Daniel; Jozwik-Plebanek, Katarzyna; Mroz, Adrianna; Janiak, Katarzyna; Gasior-Perczak, Danuta; Trofimiuk-Muldner, Malgorzata; Sowa-Staszczak, Anna; Braziewicz, Janusz; Lenda-Tracz, Wioletta; Kacperski, Krzysztof; Budzynska, Anna; Kubik, Agata; Pastusiak, Patrycja; Chalewska, Wioletta; Borkowska, Anna; Cegla, Paulina; Walecka-Mazur, Agata; Szczodry, Artur; Kaminski, Grzegorz. (2025). Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.. Frontiers in endocrinology, 16, 1716247. https://doi.org/10.3389/fendo.2025.1716247